ScoreWhy is Spero Therapeutics, Inc. ?
1
Poor Management Efficiency with a low ROE of 5.97%
- The company has been able to generate a Return on Equity (avg) of 5.97% signifying low profitability per unit of shareholders funds
2
The company has declared Negative results for the last 3 consecutive quarters
- NET SALES(9M) At USD 26.27 MM has Grown at -67.98%
- NET PROFIT(9M) At USD -35.32 MM has Grown at -270.95%
- OPERATING CASH FLOW(Y) Lowest at USD -32.33 MM
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 103.48%, its profits have fallen by -339.3%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Spero Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Spero Therapeutics, Inc.
96.55%
0.25
255.16%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
23.85%
EBIT Growth (5y)
3.16%
EBIT to Interest (avg)
-40.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.39
Sales to Capital Employed (avg)
0.98
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
34.29%
ROCE (avg)
20.70%
ROE (avg)
5.97%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.13
EV to EBIT
-1.04
EV to EBITDA
-1.04
EV to Capital Employed
-6.98
EV to Sales
3.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-203.20%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend17What is working for the Company
NET SALES(Q)
Highest at USD 11.8 MM
OPERATING PROFIT(Q)
Highest at USD -4.75 MM
OPERATING PROFIT MARGIN(Q)
Highest at -40.23 %
PRE-TAX PROFIT(Q)
Highest at USD -1.62 MM
NET PROFIT(Q)
Highest at USD -1.62 MM
EPS(Q)
Highest at USD -0.03
-15What is not working for the Company
NET SALES(9M)
At USD 26.27 MM has Grown at -67.98%
NET PROFIT(9M)
At USD -35.32 MM has Grown at -270.95%
OPERATING CASH FLOW(Y)
Lowest at USD -32.33 MM
ROCE(HY)
Lowest at -94.59%
RAW MATERIAL COST(Y)
Grown by 101.01% (YoY
CASH AND EQV(HY)
Lowest at USD 80.08 MM
Here's what is working for Spero Therapeutics, Inc.
Net Sales
At USD 11.8 MM has Grown at 96.14%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Sales
Highest at USD 11.8 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD -4.75 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at -40.23 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD -1.62 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -1.62 MM has Grown at 90.95%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -1.62 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Profit
At USD -1.62 MM has Grown at 90.95%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.03
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Here's what is not working for Spero Therapeutics, Inc.
Operating Cash Flow
Lowest at USD -32.33 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Cash and Eqv
Lowest at USD 80.08 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 101.01% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
